Maintain your gut health on the go with our Sensitive Probiotic capsules, designed to avoid common negative reactions
According to FDA labeling, no dose adjustment is required in patients with renal impairment, including those with end-stage renal disease (ESRD)
Given the results from recent studies, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend that patients with T2D and clinical cardiovascular disease (CVD) with inadequate glucose control despite treatment with metformin should receive an SGLT2 inhibitor or GLP-1 receptor agonist
The values were recorded automatically every 30 s
For healthcare professionals, this approval provides a new treatment option to help us address cardiovascular residual risk that remains for patients on current standard of care. Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight, said John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research